select a format

Single User License
USD 250 INR 16045
Site License
USD 500 INR 32090
Corporate User License
USD 750 INR 48135

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Marina Biotech Inc (MRNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Marina Biotech Inc (MRNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31603D
  • |
  • Pages: 50
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Marina Biotech Inc, formerly MDRNA Inc (Marina), is a oligonucleotide-based drug discovery and development company. It undertakes the discovery, development and commercialization of therapeutic products for rare and orphan diseases by utilizing the nucleic acid drug discovery platforms. Marina's pipeline includes clinical program CEQ508, which is being developed for familial adenomatous polyposis, and two preclinical programs for the treatment of type 1 myotonic dystrophy and duchenne muscular dystrophy. It develops nucleic acid chemistry and delivery technologies to form nucleic acid-based drug discovery, an integrated drug discovery platform. This platform targets two types of RNA, namely, coding RNA and non-coding RNA. Marina has partnering and licensing agreements with various companies such as ProNAi Therapeutics, Mirna Therapeutics, MiNA, Rosetta, Arcturus, Novartis and Tekmira, among others. Marina is headquartered in Bothell, Washington, the US.

Marina Biotech Inc (MRNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Marina Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 12

Venture Financing 13

Marina Biotech Raises USD0.3 Million in Financing Round 13

Partnerships 13

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 13

Marina Biotech Enters Into Co-Development Agreement With Girindus 15

Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 16

Merger 17

Marina Biotech and IthenaPharma Merges 17

Licensing Agreements 18

Marina Biotech Enters into Licensing Agreement for SMARTICLES 18

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 18

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 19

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 20

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 21

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 22

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 23

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 24

Marina Biotech Enters Into Licensing Agreement With Mirna Therapeutics For MicroRNA Therapeutics 25

Equity Offering 27

Marina Biotech to Raise USD1 Million in Private Placement of Preferred Stock 27

Marina Biotech Announces Private Placement Of Shares For US$6 Million 28

Marina Biotech Completes Private Placement Of Shares For US$2 Million 29

Marina Biotech Announces Private Placement Of Shares For US$1.2 Million 30

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 31

Marina Biotech Completes An Underwritten Public Offering Of Units For US$6.9 Million 32

Marina Biotech Completes Public Offering Of Units For US$5 Million 34

Marina Biotech Inc-Key Competitors 36

Key Employees 37

Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

May 17, 2016: Marina Biotech Provides First Quarter 2016 Financial Reports and Business Update 39

Mar 31, 2016: Marina Biotech Provides 2015 Year-End Financials and Update 41

Corporate Communications 43

Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 43

Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 44

Dec 14, 2016: Philippe P. Calais to Join Marina Biotech's Board of Directors 45

Jun 02, 2016: Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French 46

Product News 47

12/27/2016: Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase 47

Other Significant Developments 48

Apr 05, 2017: Marina Biotech Provides Business Update 48

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Marina Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Marina Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Marina Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 12

Marina Biotech Raises USD0.3 Million in Financing Round 13

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 13

Marina Biotech Enters Into Co-Development Agreement With Girindus 15

Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 16

Marina Biotech and IthenaPharma Merges 17

Marina Biotech Enters into Licensing Agreement for SMARTICLES 18

Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 18

Hongene Biotech Enters into Licensing Agreement with Marina Biotech 19

Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 20

Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 21

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 22

Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 23

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 24

Marina Biotech Enters Into Licensing Agreement With Mirna Therapeutics For MicroRNA Therapeutics 25

Marina Biotech to Raise USD1 Million in Private Placement of Preferred Stock 27

Marina Biotech Announces Private Placement Of Shares For US$6 Million 28

Marina Biotech Completes Private Placement Of Shares For US$2 Million 29

Marina Biotech Announces Private Placement Of Shares For US$1.2 Million 30

Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 31

Marina Biotech Completes An Underwritten Public Offering Of Units For US$6.9 Million 32

Marina Biotech Completes Public Offering Of Units For US$5 Million 34

Marina Biotech Inc, Key Competitors 36

Marina Biotech Inc, Key Employees 37

Marina Biotech Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Marina Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com